https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ASGLT2_inhibitor%2F5%2FenTranslations:SGLT2 inhibitor/5/en - Revision history2026-09-01T15:11:49ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/5/en&diff=113834&oldid=prevFuzzyBot: Importing a new version from external source2024-02-12T10:46:17Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>A meta-analysis including 13 cardiovascular outcome trials found that SGLT-2 inhibitors reduce the risk for three-point [[Major adverse cardiovascular events|MACE]], especially in subjects with an [[estimated glomerular filtration rate]] (eGFR) below 60 ml/min, whereas [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] were more beneficial in persons with higher eGFR. Likewise, the risk reduction due to SGLT-2 inhibitors was larger in populations with a higher proportion of [[albuminuria]], but this relationship was not observed for GLP-1 receptor agonists. This suggests a differential use of the two substance classes in patients with preserved and reduced renal function or with and without [[diabetic nephropathy]], respectively.</div>FuzzyBot